

RealRate

PHARMACEUTICAL 2019

Intra-Cellular Therapies Inc. Rank 81 of 363









PHARMACEUTICAL 2019





Intra-Cellular Therapies Inc. Rank 81 of 363

The relative strengths and weaknesses of Intra-Cellular Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra-Cellular Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 117% points. The greatest weakness of Intra-Cellular Therapies Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 161% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	355,439
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,299
Liabilities, Non-Current	0
Other Assets	608
Other Compr. Net Income	131
Other Expenses	1.6
Other Liabilities	3,192
Other Net Income	7,141
Other Revenues	0
Property and Equipment	1,160
Research and Development	132,167
Selling, General and Administrative Expense	30,100

Output Variable	Value in 1000 USD
Assets	357,206
Liabilities	39,492
Expenses	162,268
Revenues	0
Stockholders Equity	317,715
Net Income	-155,127
Comprehensive Net Income	-155,062
Economic Capital Ratio	197%

